Can we predict the IVF/ICSI live birth rate?

OBJECTIVES: To find a pretreatment predictor for achieving a live birth. Assisted reproduction technology with IVF/ICSI is the ultimate chance for some couples to conceive a child. The expectations are high and it is important to give them a realistic perspective about the chances of achieving a live birth. METHODS: A retrospective cohort study of all IVF/ICSI cycles performed in our center between 2012 and 2016. We considered only those cycles with a live birth delivery after 24 weeks, or cycles with no surplus embryos left. The following data was evaluated: AMH; AFC; age; BMI; previous diagnosis; type of treatment; number of previous deliveries; ethnicity, smoking status. Univariate and multivariate analysis were used to examine the association of live birth with baseline patient characteristics. We determined the odds-ratio for all the statistically significant variables (p<0.05), in a multivariate model. The results are presented according to the predictors founded. RESULTS: 739 cycles were evaluated: 9.1% were canceled; 10.2% did not have oocytes; 15.6% did not have D2 embryos; 31.4% achieved a live birth. The univariate analysis revealed statistically significant differences regarding AMH, AFC and women's age between couples with and without a live birth (p<0.001), and the cause of infertility. We found no association with live births in other variables. These variables were categorized and used in a multivariate analysis. CONCLUSION: Age, AMH, AFC and cause, when sub-classified, are independently associated with the results of an IVF/ICSI treatment. These results enable couples to face real expectations in their particular scenario.

Double Cervix with Normal Uterus and Vagina - An Unclassified Müllerian Anomaly.

Müllerian anomalies are very common, and a frequent cause of infertility. The most used classification system until now, proposed by the American Society for Reproductive Medicine in 1988, categorizes comprehensively uterine anomalies but fails to classify defects of the cervix or vagina. This is based on a developmental theory that postulates that müllerian duct fusion is unidirectional, beginning caudally and extending cranially, which does not account for isolated cervical or vaginal defects. More recently, the European Society of Human Reproduction and Embryology has developed a consensus, which allows for independent cervical anomalies. We present a case of a 39-year-old woman with secondary infertility, found to have a cervical duplication in an anteroposterior disposition, which puts into question the principles of embryology formerly known, but supports the theory that development happens in a segmentary fashion.

Previsão de gravidez pós-fertilização in vitro de acordo com valor de ß-hCG e progesterona / Prediction of pregnancy after in vitro fertilization according ß-hCG and progesterone levels

Introdução: Múltiplos estudos sugerem que os valores de ß-hCG e de progesterona podem ser bons preditores de gravidez. Objetivo: Investigar o potencial dos valores de ß-hCG e progesterona na previsão de gravidez evolutiva e de gravidez gemelar, 14 dias após punção ovocitária em ciclos FIV/ICSI, e estabelecer um modelo de previsão. Métodos: Estudo retrospetivo de ciclos com punção e transferência de embriões a fresco entre maio/2011 e setembro/2015. Os grupos definidos foram: sem gravidez; gravidez não evolutiva; gravidez evolutiva (única ou gemelar). A análise estatística considerou = 5%. Para avaliar a capacidade de prever gravidez evolutiva e gravidez gemelar recorreu-se a um modelo de análise multivariada e usou-se um processo de regressão logística binária. Recorreu-se às curvas ROC para avaliar a capacidade do valor de ß-hCG e progesterona na distinção entre gravidez não evolutiva e evolutiva. Resultados: Verificaram-se 149 casos: sem gravidez 11,4%, gravidez não evolutiva 24,8%, gravidez evolutiva 63,8% (83 única, 12 gemelares). Com exceção dos valores de progesterona e ß-hCG, não se verificaram diferenças estatisticamente significativas entre as variáveis do grupo gravidez não evolutiva e evolutiva (ß-HCG: 38,9 vs 159 UI/L; progesterona: 20,4 vs 60 ng/mL). Na comparac¸ão entre gravidez única e gemelar, apenas o valor de ß-hCG foi estatisticamente significativo (ß-HCG: 147 vs 331 UI/L). Quando o valor de progesterona é ≥ 25, a probabilidade de gravidez é 5,4 vezes superior (IC95%, 1,18-24,8). Na regressão logística para gravidez gemelar apenas o valor de ß-hCG foi estatisticamente significativo. Conclusão: Uma avaliação única de progesterona e ß-hCG, 14 dias após punção, tem um bom valor preditivo de gravidez evolutiva, porém com capacidade limitada para discriminar entre gravidez única e gemelar.(AU)

Introduction: Multiple studies suggest that the amount of ß-hCG and progesterone can be good predictors of pregnancy. Objective: To investigate the potential of ß-hCG and progesterone values in predicting evolutive pregnancy and twin pregnancy, 14 days after oocyte puncture in IVF/ICSI cycles, establishing a predictive model. Methods: A retrospective study of cycles with the use of a puncture and fresh embryo transfer between May/2011 and September/2015. The defined groups were: with no pregnancy; without evolutive pregnancy; and with evolutive (single or twin) pregnancy. Statistical analysis considered = 5%. To assess the ability to predict evolutive pregnancy and twin pregnancy, a multivariate analysis model was carried out, with the use of a binary logistic regression process. ROC curves were used to evaluate the ability of ß-hCG and progesterone values in differentiating between non-evolutive and evolutive pregnancy. Results: 149 cases were found: no pregnancy 11.4%, without evolutive pregnancy 24.8%, with evolutive pregnancy 63.8% (83 single, 12 twins). Excluding progesterone and ß-hCG values, there were no statistically significant differences between the variables of non-evolutive and evolutive pregnancy groups (ß-HCG: 38.9 vs. 159 IU/L, progesterone: 20.4 vs. 60ng/mL). In a comparison between single and twin pregnancies, only the amount of ß-hCG was statistically significant (ß-HCG: 147 vs. 331 IU/L). When progesterone value is >25, the probability of pregnancy is 5.4 times greater (95% CI, 1.18-24.8). In a logistic regression for twin pregnancies, only ß-hCG value was statistically significant. Conclusion: A single assessment of progesterone and ß-hCG values 14 days after the puncture has a good predictive value of evolutive pregnancy, but with limited ability to discriminate between single and twin pregnancies.(AU)

Preservação da fertilidade em doentes oncológicos ou sob terapêutica gonadotóxica: estado da arte / Fertility preservation in oncologic patients or undergoing gonadotoxic therapies: state of art

O câncer não é incomum nem incurável: 85% dos doentes com menos de 45 anos diagnosticados nos EUA em 2002 sobreviveram mais de 10 anos. As maiores taxas de sobrevivência verificam‐se nos doentes jovens com câncer da mama, testicular e hematológico. Contudo, é para tratar estes tumores que são usados os fármacos mais gonadotóxicos, assim como doenças hematológicas e autoimunes também requerem terapêuticas potencialmente lesivas para as gônadas para o seu controle. O comité ético da Sociedade Americana de Medicina da Reprodução considera que “existem fortes argumentos para a preservação da fertilidade em doentes jovens com cânceres tratáveis”. Cabe ao médico assistente (oncologista, hematologista, cirurgião, internista) decidir o tratamento do paciente e considerar: o risco de falência ovárica/testicular; o prognóstico e o timing para iniciar tratamentos. Por outro lado, ao especialista em medicina da reprodução cabe desenvolver estratégias para preservar gâmetas/embriões de acordo com idade, tempo disponível até início do tratamento, tipo de câncer, status marital e risco de infertilidade com a terapêutica proposta. A colaboração contínua entre esses especialistas, incluindo os doentes e os parceiros, é a chave para a tomada de decisões que permitam a preservação da função reprodutiva após controle da doença de base.

Cancer is not unusual neither incurable: in USA 85% of patients under 45 years diagnosed in 2002 survived more than 10 years. The highest survival rates occur in young patients with breast, testicular and hematologic cancer. However, these tumors are treated with drugs wich most affect fertility and there is evidence that the discussion of preserving fertility is of great importance. Moreover, hematologic and autoimmune diseases may also require the use of potentially gonadotoxic drugs for their control. The ethics committee of the American Society for Reproductive Medicine believes that “there are strong arguments for the preservation of fertility in young patients with treatable cancers”. It is up to the physician (oncologist, hematologist, surgeon, internist) to decide the best treatment to the patient evaluating the risk of ovarian/testicular failure; the prognosis and the timing to start treatments. Moreover, the specialist in reproductive medicine should develop strategies to preserve gametes/embryos according to: age; time to treatment; type of cancer; marital status and risk of infertility, with the proposed therapy. The ongoing collaboration between these specialists, including patients and partners in the discussion, is the key to making decisions that allow the preservation of reproductive function after control of the primary disease.

[Thyroid associated ophthalmopathy]. / Oftalmopatia associada à tiroide.

Thyroid associated ophthalmopathy is an uncommon disease, characterized by a diffuse inflammation of the orbit in a bilateral and asymmetric pattern, causing proptosis and swelling of the eyelids and conjuntiva. In 90% of the patients it is associated with Graves' disease, however it may occur with hipothyroidism or even without thyroid disease. During its course spontaneous remission or exacerbations are common, evolving independently from the thyroid disease, most often without serious complications for the patient, being blindness the worse of them, in 1% of the cases. The cause is still misunderstood but it is thought to be the result of an immune system disorder with the production of auto-antibodies directed against retro-bulbar fibroblasts and thyroid. Therapeutics is still a controversial matter. The balance between benefits and medication adverse effects is still to be made.